Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Aims At Alzheimer’s, Adds Proteostasis As Neurodegenerative Partner

This article was originally published in The Pink Sheet Daily

Executive Summary

In a new deal with Proteostasis, Biogen Idec reaffirms its interest in establishing itself in some of the most intractable, hard-to-treat neurodegenerative diseases, such as Parkinson’s and Alzheimer’s.

You may also be interested in...



Tecfidera Takes Off In U.S., Clarity For EU Launch Likely Soon

Biogen Idec’s launch of the drug continued to surpass Wall Street’s expectations, in its third quarter earnings. Its potential EU marketing of Tecfidera hangs in the balance, with news likely on Nov. 22 from CHMP. The biotech also highlighted its approval and pipeline expectations for 2014.

Biogen Reports Progress In Late-Stage Programs, Plus Some Bumps In The Road

Biogen Idec reported steady progress in the clinic for four late-stage programs, including hemophilia. Recent bumps include a three-month delay for the MS product BG-12, but nothing that would derail its Phase III pipeline.

Proteostasis Teams Up With Elan In $50M Neurodegenerative Collaboration

Irish company will get a 24% stake in the U.S. biotech as part of an R&D collaboration centered around neurodegenerative diseases.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS075236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel